TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07303465: A Study to Evaluate the Efficacy and Safety of RNK08954 in Subjects With KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

Sponsor: Ranok Therapeutics (Hangzhou) Co., Ltd. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 60 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT07303465 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07303465 Rescue Dossier →